With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Mounjaro (tirzepatide) : Lilly's dual GIP/GLP-1 agonist has delivered best-in-class weight loss and glycemic control in T2D and, under its obesity brand Zepbound , has outperformed semaglutide in head ...

Here's what investors need to know. On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had ...

MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious ...

The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.

A draft copy of an upcoming MAHA report reveals a strategy in lockstep with recent HHS actions such as reviving the Task ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

Wegovy is now positioned as the first and only GLP-1 treatment.

When Opill became available a year ago, public health experts anticipated it would benefit women without health insurance and those residing in rural areas. The goal was to boost access to ...

This episode of Pharma Pulse covers Novo Nordisk’s FDA win for Wegovy in MASH-related liver fibrosis, new research on a ...